Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondrial retrograde signal through GCN5L1 transition–mediated PPARγ stabilization promotes MASLD development
Jiaqi Zhang, Danni Wang, Qiqi Tang, Yaoshu Yue, Xin Lu, Xiuya Hu, Yitong Han, Jiarun Chen, Zihan Wang, Xue Bai, Kai Zhang, Yongsheng Chang, Longhao Sun, Lu Zhu, Lingdi Wang
Jiaqi Zhang, Danni Wang, Qiqi Tang, Yaoshu Yue, Xin Lu, Xiuya Hu, Yitong Han, Jiarun Chen, Zihan Wang, Xue Bai, Kai Zhang, Yongsheng Chang, Longhao Sun, Lu Zhu, Lingdi Wang
View: Text | PDF
Research Article Cell biology Hepatology

Mitochondrial retrograde signal through GCN5L1 transition–mediated PPARγ stabilization promotes MASLD development

  • Text
  • PDF
Abstract

Mitochondrial retrograde signaling plays crucial roles in maintaining metabolic homeostasis via regulating genome modification and oxidative responsive gene expression. In this study, we identified GCN5L1, a protein localized in both mitochondria and cytoplasm, and demonstrated its specific translocation from mitochondria to cytoplasm during lipid overload and high-fat diet feeding. Using transcriptome and proteome analyses, we identified that cytoplasmic GCN5L1 binds to and promotes the acetylation of PPARγ at lysine 289 (K289). This acetylation protected PPARγ from ubiquitination-mediated degradation by proteasome. GCN5L1 translocation enhanced protein stability of PPARγ and subsequently promoted lipid accumulation in both cultured cells and murine models. Our study further reveals that PPARγ-K289 mutation reduces the ubiquitination of PPARγ and exacerbates liver steatosis in mice. These findings unveil a mitochondrial retrograde signaling during lipid overload, which regulates the crucial lipogenic transcriptional factor. This discovery elucidates an unrecognized mitochondrial function and mechanism underlying hepatic lipid synthesis.

Authors

Jiaqi Zhang, Danni Wang, Qiqi Tang, Yaoshu Yue, Xin Lu, Xiuya Hu, Yitong Han, Jiarun Chen, Zihan Wang, Xue Bai, Kai Zhang, Yongsheng Chang, Longhao Sun, Lu Zhu, Lingdi Wang

×

Figure 6

GCN5L1 modulates PPARγ-K289 acetylation to prevent ubiquitination and degradation.

Options: View larger image (or click on image) Download as PowerPoint
GCN5L1 modulates PPARγ-K289 acetylation to prevent ubiquitination and de...
(A) HepG2 control or GCN5L1-myc–overexpressing cells were transfected with PPARγ-FLAG. Immunoprecipitation was performed using a FLAG antibody to detect the acetylation level of PPARγ-FLAG. Quantitation of 4 independent experiments is shown. (B) Coimmunoprecipitation (co-IP) was performed to validate the interaction between PPARγ-FLAG and GCN5L1-myc. Immunoprecipitation was conducted using an anti-myc antibody. (C) Co-IP assays were performed to validate the interaction between PPARγ-FLAG and GCN5L1-myc. Immunoprecipitation was conducted using an anti-FLAG antibody. (D) Co-IP was performed to validate the interaction between PPARγ and GCN5L1-myc. GCN5L1-myc was precipitated from AAV-GCN5L1-myc or AAV-eGFP mice. PPARγ was assessed by immunoblotting. Quantitation of input PPARγ levels in livers from AAV-GCN5L1-myc or AAV-eGFP mice is shown (right) (data from 4 independent experiments). (E) Illustration indicates domains of PPARγ. (F) Co-IP validation of the interaction of PPARγ-FLAG domains with GCN5L1-myc. (G) Illustration of the procedures to identify ubiquitination or acetylation residues of PPARγ by immunoprecipitation coupled with mass spectrometry. (H) PPARγ ubiquitination or acetylation residues were detected in HepG2 cells. Red marks the increased modification in GCN5L1-KO cells for ubiquitinated lysine residues or in GCN5L1-myc cells for acetylated lysine residues in D domain; blue-labeled K293 exhibited no significant variance between the control and GCN5L1 KO. PSM, peptide spectrum match. (I) PPARγ-wild-type or -K289R plasmids, along with the ubiquitin-myc (Ub-myc) plasmid, were cotransfected into HepG2 CON or GCN5L1-KO cells. PPARγ-FLAG or PPARγ-K289R-FLAG was immunoprecipitated to assess the ubiquitination levels by immunoblotting. (J) HepG2 CON or GCN5L1-myc–overexpressing cells were transfected with PPARγ-K289R-FLAG. PPARγ-K289R-FLAG was immunoprecipitated to assess the acetylation levels by immunoblotting. Datasets in A and D were analyzed by non-parametric statistical tests. *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts